Thus, other drugs that inhibit ET-1 signaling such as empagliflozin43,44 could be considered instead of atrasentan.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: Although some cancer therapies have overt and/or subclinical cardiotoxic effects that increase subsequent cardiovascular risk in breast cancer patients, women with breast cancer exhibit relative cardiac remodeling and cardiac dysfunction even before chemotherapy. Here, EDN1 is linked to cancer.